PROFILE OF NEGATIVE DISORDERS IN THE STRUCTURE OF SOCIAL MALADDAPTATION IN PARANOID SCHIZOPHRENIA PATIENTS
Keywords:
paranoid schizophrenia, negative symptoms, social maladaptation, avolition, anhedonia, schizophreniaAbstract
Paranoid schizophrenia is characterized by a combination of positive (productive) and negative symptoms; however, negative disorders play a leading role in the development of long-term social maladaptation in patients. Negative symptoms include affective flattening, avolition, alogia, anhedonia, and social withdrawal, which significantly reduce the level of social and occupational functioning. The aim of this study is to analyze the profile of negative disorders in patients with paranoid schizophrenia and to assess their contribution to the structure of social maladaptation. It has been demonstrated that the severity of negative symptoms is more strongly associated with impaired social adaptation than positive psychotic symptoms. The obtained data confirm that negative disorders are a key predictor of chronic disability in schizophrenia and require targeted rehabilitation approaches. Early identification and correction of negative symptoms are of particular importance for improving patients’ social functioning.
References
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5-TR. Washington (DC): American Psychiatric Association Publishing; 2022.
World Health Organization. International statistical classification of diseases and related health problems. 10th revision. Geneva: WHO; 2019.
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982;39(7):784–788.
Carpenter WT Jr, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578–583.
Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214–219.
Harvey PD, Strassnig MT, Silberstein J. Prediction of disability in schizophrenia: symptoms, cognition, and self-assessment. J Exp Psychopathol. 2019;10(3):204380871986569.
Green MF. Impact of cognitive and social cognitive impairment on functional outcomes in schizophrenia. J Clin Psychiatry. 2016;77(2):8–11.
Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150(1):3–10.
Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? CNS Spectr. 2007;12(S17):1–13.
Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664–677.
Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam’s razor. Schizophr Bull. 2010;36(2):359–369.
Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017;16(1):14–24.
Liddle PF. The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. Br J Psychiatry. 1987;151:145–151.
Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci. 2012;16(1):27–34.
Kring AM, Elis O. Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol. 2013;9:409–433.
Strauss GP, Cohen AS. A transdiagnostic review of negative symptom phenomenology. Schizophr Bull. 2017;43(4):713–719.
Harvey PD, Strassnig MT. Predicting the severity of everyday functional disability in people with schizophrenia. World Psychiatry. 2012;11(2):97–105.
Lin CH, Lane HY. Early identification and intervention of schizophrenia: focus on negative symptoms. Adv Exp Med Biol. 2019;1145:127–145.
Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24(5):645–692.
Downloads
Published
Issue
Section
How to Cite
